CO5200833A1 - Regimenes de dosificacion para lasofoxifeno - Google Patents

Regimenes de dosificacion para lasofoxifeno

Info

Publication number
CO5200833A1
CO5200833A1 CO00074167A CO00074167A CO5200833A1 CO 5200833 A1 CO5200833 A1 CO 5200833A1 CO 00074167 A CO00074167 A CO 00074167A CO 00074167 A CO00074167 A CO 00074167A CO 5200833 A1 CO5200833 A1 CO 5200833A1
Authority
CO
Colombia
Prior art keywords
lasofoxifeno
dosage regimes
antagonist
estrogen agonist
medicament
Prior art date
Application number
CO00074167A
Other languages
English (en)
Inventor
Thompson David Duane
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5200833A1 publication Critical patent/CO5200833A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

El uso de un agonista/antagonista de estrógeno para la manufactura de un medicamento para ser administrado oralmente y en suficiente cantidad con el objetivo de mantener un nivel sanguíneo seguro y efectivo de un agonista/antagonista de estrógeno por un largo periodo de tiempo.
CO00074167A 1999-09-29 2000-09-29 Regimenes de dosificacion para lasofoxifeno CO5200833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15665299P 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
CO5200833A1 true CO5200833A1 (es) 2002-09-27

Family

ID=22560457

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00074167A CO5200833A1 (es) 1999-09-29 2000-09-29 Regimenes de dosificacion para lasofoxifeno

Country Status (20)

Country Link
US (1) US6436977B1 (es)
EP (1) EP1092431B1 (es)
JP (1) JP2001097862A (es)
KR (1) KR100468246B1 (es)
AT (1) ATE339201T1 (es)
AU (1) AU781828B2 (es)
CA (1) CA2321369C (es)
CO (1) CO5200833A1 (es)
CY (1) CY1105235T1 (es)
DE (1) DE60030654T2 (es)
DK (1) DK1092431T3 (es)
ES (1) ES2269071T3 (es)
HU (1) HUP0003836A3 (es)
IL (1) IL138634A (es)
MY (1) MY121519A (es)
NZ (2) NZ516413A (es)
PE (1) PE20010680A1 (es)
PT (1) PT1092431E (es)
TW (1) TWI224001B (es)
ZA (1) ZA200005141B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
CA2452871C (en) 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (en) 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications

Also Published As

Publication number Publication date
CY1105235T1 (el) 2010-03-03
HUP0003836A3 (en) 2002-09-30
KR100468246B1 (ko) 2005-01-27
IL138634A0 (en) 2001-10-31
NZ507200A (en) 2004-12-24
NZ516413A (en) 2004-12-24
ZA200005141B (en) 2002-03-26
TWI224001B (en) 2004-11-21
CA2321369C (en) 2007-07-17
EP1092431A3 (en) 2002-02-13
IL138634A (en) 2006-08-01
EP1092431B1 (en) 2006-09-13
ES2269071T3 (es) 2007-04-01
US6436977B1 (en) 2002-08-20
DK1092431T3 (da) 2006-12-18
EP1092431A2 (en) 2001-04-18
ATE339201T1 (de) 2006-10-15
PE20010680A1 (es) 2001-06-29
AU781828B2 (en) 2005-06-16
DE60030654T2 (de) 2007-04-05
AU5661800A (en) 2001-04-05
JP2001097862A (ja) 2001-04-10
CA2321369A1 (en) 2001-03-29
MY121519A (en) 2006-01-28
HUP0003836A2 (hu) 2001-10-28
HU0003836D0 (en) 2000-12-28
KR20010061927A (ko) 2001-07-07
PT1092431E (pt) 2006-12-29
DE60030654D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
CO5200833A1 (es) Regimenes de dosificacion para lasofoxifeno
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
EE9900288A (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
AR018582A1 (es) Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
CO5540373A2 (es) Composicion farmaceutica de liberacion sostenida
DK1112060T3 (da) Doseringsform anvendende flydende formulering
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
AR027287A1 (es) Gonadotrofina
AR007058A1 (es) Uso de interferon en medicamentos y composiciones para contacto oromucosal
EA200200839A1 (ru) Композиции с контролируемым высвобождением, содержащие агонист и антагонист опиоидов
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração
ECSP982720A (es) Formulacion que contiene un opioide en combinacion con un agonista adrenergico y su utilizacion como analgesico
SE0001428D0 (sv) Treatment of hypertrophic cardiomyopathy with a substance that decreases the level of igf-i
TH35545A (th) วิธีการบำบัดการขยายตัวผิดปกติของต่อมลูกหมากและมะเร็งของต่อมลูกหมาก

Legal Events

Date Code Title Description
FC Application refused